MRK's Keytruda Combo Fails in Phase III Colorectal Cancer Study [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
Merck MRK announced data from the phase III KEYFORM-007 study, which evaluated a fixed-dose combination of its anti-LAG-3 antibody, favezelimab and its blockbuster anti-PD-1 therapy, Keytruda in pre-treated patients with PD-L1 positive microsatellite stable (MSS) metastatic colorectal cancer (mCRC). The study failed to meet the primary endpoint of overall survival (OS). Year to date, shares of Merck have gained 5.2% compared with the industry's rise of 22.8%. Image Source: Zacks Investment Research What Did MRK's KEYFORM-007 Study Show? The randomized phase III KEYFORM-007 study evaluated the fixed-dose combination of favezelimab and Keytruda compared to standard of care, regorafenib for the treatment of patients with PD-L1 positive MSS mCRC who were previously treated with standard therapies. At the final pre-specified analysis, treatment with favezelimab + Keytruda failed to demonstrate an improvement in OS versus standard of care – regorafenib in the given patient popu
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Summit Therapeutics downgraded at Citi on valuation [Seeking Alpha]Seeking Alpha
- Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024Business Wire
- Merck & Co. Inc. (MRK): A Good Undervalued Blue Chip Stock to Buy According to Analysts [Yahoo! Finance]Yahoo! Finance
- Merck's colorectal cancer therapy fails late-stage trial [CNBC]CNBC
- ADHD Redefined: ADDitude Honors ADHD Empowerment Month with Groundbreaking Campaign [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 7/30/24 - Beat
MRK
Sec Filings
- 8/6/24 - Form 4
- 8/5/24 - Form 10-Q
- 7/30/24 - Form 8-K
- MRK's page on the SEC website